No Mercy / No Malice: The Weight

What It Covers

Scott Galloway argues GLP-1 drugs represent the most transformative technology in the US economy, with obesity rates declining for the first time in decades, while access inequality and insurance rollbacks threaten to limit their societal impact.

Key Questions Answered

• •GLP-1 Market Expansion: Eli Lilly's stock rose 418% since 2021 GLP-1 approval, reflecting the category's explosive growth. New drugs like retatrutide show 29% body weight loss at 12mg doses, while the FDA-approved daily pill Orforglipron offers an alternative for the 66 million Americans who avoid needles.
• •Access as the Core Barrier: A Cleveland Clinic study found 47% of GLP-1 discontinuations stem from cost — insurance denial, expired coupons, or unaffordable out-of-pocket expenses. Only 14% quit due to side effects. Medicare Part D coverage beginning July 1 caps costs at $50 monthly, but private insurers are scaling back.
• •Consumer Behavior Shift: GLP-1 users consume 21% fewer calories and spend nearly one-third less on groceries. Fast food chains including Jack in the Box and Wendy's are closing hundreds of locations amid 500-plus franchisee bankruptcies, while Victoria's Secret surged 47% on revenue growth tied to shifting body size trends.
• •Pharmaceutical Economics Reversal: Eli Lilly CEO David Ricks confirmed GLP-1 pricing behaves unlike traditional drugs — demand rises as prices fall, making this a rare case of elastic pharmaceutical pricing. However, the long-term dependency model mirrors a subscription business with monthly costs between $149 and $499.